A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer

Matsumura, Shunji; Oue, Naohide; Kitadai, Yasuhiko; Chayama, Kazuaki; Yoshida, Kazuhiro; Yamaguchi, Yoshiyuki; Toge, Tetsuya; Imai, Kazue; Nakachi, Kei; Yasui, Wataru

doi:10.1007/s00432-004-0543-1

Cited by 39 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar gender differences in risk for the MMP-1 polymorphism were also found for renal cell and gastric cancer patients (16,17). Sex hormones including progesterone, estradiol, and ovarian steroids levels may decrease the MMP-1 expression levels and increase the tissue inhibitor levels of MMP-1 proteins (18)(19)(20).…”

Section: Discussionmentioning

confidence: 59%

Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk

Li¹,

Zhou²,

Park

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Extracellular matrix-degrading matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades the interstitial types I, II, and III collagens, and overexpression of MMP-1 is associated with cancer development and cellular invasion. The 2G allele of the MMP-1 À1607 1G/2G polymorphism is associated with enhanced transcriptional activity. We investigated the association between the MMP-1 1G/2G polymorphism and lung cancer risk in 1,752 Caucasian lung cancer patients and 1,363 healthy controls. There were no overall associations between the MMP-1 genotypes and risk of lung cancer, with the adjusted odds ratios of 1.15 [95% confidence interval (CI), 0.94-1.40] for the 1G/2G genotype and 1.14 (95% CI, 0.90-1.45) for the 2G/2G genotype, when versus the 1G/1G genotype. Stratified analyses suggested higher lung cancer risk for the 2G allele in never-smokers and males, with the adjusted odds ratios of 1.67 (95% CI, 1.02-2.76; 1G/2G) and 1.50 (95% CI, 0.86-2.62; 2G/2G) in never-smokers; and 1.30 (95% CI, 1.00-1.75; 1G/2G) and 1.23 (95% CI, 0.88-1.73; 2G/2G) in males, respectively. In conclusion, genotypes containing the 2G allele of the MMP-1 polymorphism are associated with higher risk of lung cancer in never-smokers and in males. (Cancer Epidemiol Biomarkers Prev 2005;14(3):567 -70)

show abstract

Section: Discussionmentioning

confidence: 59%

Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk

Li¹,

Zhou²,

Park

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…The SNPs of MMP1 (1607 1G/2G), MMP3 (1171 5A/6A), MMP7 (153 C/T), MMP8 (17 C/G) and MMP8 (799 C/T) are reported not to be associated with gastric cancer risk or prognosis [14,42,44,65] . AG genotype of the MMP13 77A/G polymorphism were reported to have a decreased risk of developing gastric cancer [39,41] .…”

Section: Gastric Cancermentioning

confidence: 99%

Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

Langers

Verspaget²,

Hommes³

et al. 2011

WJGO

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) are implicated in cancer development and progression and are associated with prognosis. Single-nucleotide polymorphisms (SNPs) of MMPs, most frequently located in the promoter region of the genes, have been shown to influence cancer susceptibility and/or progression. SNPs of MMP-1, -2, -3, -7, -8, -9, -12, -13 and -21 and of the tissue inhibitor of metalloproteinases (TIMPs) TIMP-1 and TIMP-2 have been studied in digestive tract tumors. The contribution of these polymorphisms to the cancer risk and prognosis of gastrointestinal tumors are reviewed in this paper.

show abstract

“…Recent epidemiological studies have demonstrated almost consistent results regarding the biological function of the MMP-1 promoter polymorphism and its association with the susceptibility or progression in several cancer types (4,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23). The 2G allele of the polymorphism has been reported to be related with increased risk of colorectal, lung, endometrial, ovary, kidney, and bladder cancers (4,(12)(13)(14)(15)(16)(17)(18)(19)(20), while the 2G allele was associated with tumor progression or patient survival but not with susceptibility of uterus, stomach, and colorectal (24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

Tsuchiya

Narita²,

Kumazawa³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Matrix metalloproteinase-1 (MMP-1) is associated with cancer invasion and metastasis. The 2G allele of the polymorphic site in the MMP-1 promoter was demonstrated to have a higher transcription activity than the 1G allele. Allelic imbalance (AI) at 11q22 harboring the MMP-1 is frequently observed in various cancers and may be associated with an advanced disease. We conducted a case-control study to determine the association of the MMP-1 genotype with susceptibility to prostate cancer involving 283 prostate cancer patients and 251 controls. Furthermore, AI, retention allele of the MMP-1 promoter, and MMP-1 protein expression were analyzed in 77 prostate cancer specimens. The MMP-1 promoter polymorphism was associated with neither susceptibility nor progression of prostate cancer. Tumors with 1G/2G and 2G/2G genotypes had a significantly higher MMP-1 expression level compared to those with 1G/1G genotype (P=0.006 and 0.013, respectively). AI at 11q22 was observed in 13 (40.6%) of 32 informative cases. Retention of the 1G and 2G alleles were observed in 4 and 9 cases, respectively. AI was significantly associated with the Gleason score (P=0.003) and pathological stage (P=0.022). In addition, retention of the 2G allele showed a significant association with the pathological stage (P=0.026). AI at 11q22 region, retention of the 2G allele, specifically appeared to be involved in the progression of prostate cancer. However, the presence of the 2G allele of the MMP-1 promoter polymorphism itself seems to influence neither the susceptibility nor the progression of prostate cancer. IntroductionTumor invasion or metastasis is one of the most crucial events for determining the outcome of cancer patients. In the first step of these events, several proteinases such as serine proteinase urokinase plasminogen activator and matrix metalloproteinases (MMPs) degrade the extra-cellular matrix (ECM), so that the tumor cells can migrate to the stromal tissue through the basement membrane (1). MMP-1, a member of MMP family, is abundantly expressed in many types of cancer cells and adjacent stromal fibroblasts (2-5), and digests various elements of the ECM including collagen types I, II, II, VII, VIII, X, and XI (6). The overexpression of MMP-1 has been shown to be associated with tumor progression and poor outcomes for cancers of the digestive system and melanoma (3,5,7,8).The expression of MMP-1 is mainly regulated by activated protein-1 (AP-1) transcription factor that mediates signal transduction from cytokines and growth factors such as interferons, interleukins, epidermal growth factor, and fibroblast growth factor (9). In the promoter region of the MMP-1, three AP-1 binding sites are located at -72, -186, and -1062 bp from the transcription start site. Insertion of an extra guanine residue adjacent to the AP-1 binding site at -1062 bp creates a new binding site for ETS transcription factor at -1602 bp (5'-AAGGAT-3'; 2G), and both the AP-1 and ETS cooperatively enhance the expression of MMP-1 (10). AP-1 binding to the -1...

show abstract

A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer

Abstract: The presence of 2G allele in the MMP-1 promoter did not enhance the risk of gastric cancer; however, it may be involved in differentiation of gastric cancer.

Cited by 39 publications

References 24 publications

Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk

Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk

Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

Contact Info

Product

Resources

About